Frontlight ResearchEarly access
Trial site
M2M Med. Sp. z o.o. Sp. j.
- 9running trials
- 5closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Conditions
- Myeloproliferative neoplasms3 trials
- Ulcerative colitis3 trials
- Alzheimer disease2 trials
- Asthma2 trials
- Acute myeloid leukaemia1 trial
- Atopic dermatitis (eczema)1 trial
- Chronic kidney disease1 trial
- Crohn's disease1 trial
- Lupus (SLE)1 trial
- Myelodysplastic syndromes1 trial
- Obesity1 trial
- Systemic sclerosis (scleroderma)1 trial
- and 1 more
- Phase
- Phase 28 trials
- Phase 36 trials
- Phase 41 trial
- Status
- Recruiting5 trials
- Completed4 trials
- Active, not recruiting3 trials
- Not yet recruiting1 trial
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- Bristol-Myers Squibb2 trials
- Eli Lilly & Co.2 trials
- Ryvu Therapeutics SA2 trials
- Alvotech Swiss AG1 trial
- Bristol-Myers Squibb Services Unlimited Company1 trial
- and 7 more
Running trials
Recruiting
Recruiting
Enrolling by invitation
Recruiting
Active, not recruiting
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Recruiting
Active, not recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Alzheimer disease2 recruiting
- Acute myeloid leukaemia1 recruiting
- Asthma1 recruiting
- Crohn's disease1 recruiting
- Myelodysplastic syndromes1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Ulcerative colitis1 recruiting
Closed trials
Completed
Completed
Terminated
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Completed
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 13 Nov 2026